These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 2598405)

  • 1. Protection against cisplatin nephrotoxicity by prochlorperazine.
    Kramer RA
    Cancer Chemother Pharmacol; 1989; 25(3):156-60. PubMed ID: 2598405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug interaction effects on antitumor drugs. XIII. Amelioration of cisplatin lethality and renal toxicity by chlorpromazine in mice.
    Ishikawa M; Takayanagi Y; Sasaki K
    Biol Pharm Bull; 1993 Nov; 16(11):1104-7. PubMed ID: 8312864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a cisplatin-chondroitin sulfate A complex in reducing the nephrotoxicity of cisplatin.
    Zhang JS; Imai T; Otagiri M
    Arch Toxicol; 2000 Aug; 74(6):300-7. PubMed ID: 11005675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amelioration of cisplatin-induced nephrotoxicity by the diuretic acetazolamide in F344 rats.
    Osman NM; Copley MP; Litterst CL
    Cancer Treat Rep; 1984; 68(7-8):999-1004. PubMed ID: 6540145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin-induced loss of kidney copper and nephrotoxicity is ameliorated by single dose diethyldithiocarbamate, but not mesna.
    DeWoskin RS; Riviere JE
    Toxicol Appl Pharmacol; 1992 Feb; 112(2):182-9. PubMed ID: 1311464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo.
    Nagai N; Ogata H
    Cancer Chemother Pharmacol; 1997; 40(1):11-8. PubMed ID: 9137523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug interaction effects on antitumour drugs (X): exacerbation of cisplatin lethality by bacterial lipopolysaccharide in mice.
    Ishikawa M; Takayanagi Y; Sasaki K
    Pharmacol Toxicol; 1991 May; 68(5):366-70. PubMed ID: 1946182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor effects of three platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-platinum (II) monohydrate (DWA2114R), cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) and cis-diamminedichloroplatinum(II) (CDDP), in mice.
    Endo K; Akamatsu K; Matsumoto T; Morikawa K; Koizumi M; Mitsui H; Koizumi K
    Anticancer Res; 1992; 12(1):49-58. PubMed ID: 1567181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-methionine antagonism of cis-platinum nephrotoxicity.
    Basinger MA; Jones MM; Holscher MA
    Toxicol Appl Pharmacol; 1990 Mar; 103(1):1-15. PubMed ID: 2315922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection effects of Taurine supplementation against cisplatin-induced nephrotoxicity in rats.
    Saad SY; Al-Rikabi AC
    Chemotherapy; 2002 Mar; 48(1):42-8. PubMed ID: 11901256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of disopyramide and verapamil on renal disposition and nephrotoxicity of cisplatin in rats.
    Hanada K; Odaka K; Kudo A; Ogata H
    Pharm Res; 1999 Oct; 16(10):1589-95. PubMed ID: 10554102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of sodium thiosulfate on the pharmacokinetics of unchanged cisplatin and on the distribution of platinum species in rat kidney: protective mechanism against cisplatin nephrotoxicity.
    Nagai N; Hotta K; Yamamura H; Ogata H
    Cancer Chemother Pharmacol; 1995; 36(5):404-10. PubMed ID: 7634382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Para-aminobenzoic acid suppression of cis-diamminedichloroplatinum(II) nephrotoxicity.
    Esposito M; Vannozzi MO; Viale M; Fulco RA; Collecchi P; Merlo F; De Cian F; Zicca A; Cadoni A; Poirier MC
    Carcinogenesis; 1993 Dec; 14(12):2595-9. PubMed ID: 8269632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antitumour effect and toxicity of cis-platinum and N-methylformamide in combination.
    Harpur ES; Langdon SP; Fathalla SA; Ishmael J
    Cancer Chemother Pharmacol; 1986; 16(2):139-47. PubMed ID: 3948299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thioether suppression of cisplatin nephrotoxicity in the rat.
    Jones MM; Basinger MA; Holscher MA
    Anticancer Res; 1991; 11(1):449-53. PubMed ID: 2018382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of 2,3-dimercapto-1-propanesulfonic acid (DMPS) and meso-2,3-dimercaptosuccinic acid (DMSA) on the nephrotoxicity in the mouse during repeated cisplatin (CDDP) treatments.
    Yajima Y; Kawaguchi M; Yoshikawa M; Okubo M; Tsukagoshi E; Sato K; Katakura A
    J Pharmacol Sci; 2017 Jun; 134(2):108-115. PubMed ID: 28648300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate.
    Bodenner DL; Dedon PC; Keng PC; Katz JC; Borch RF
    Cancer Res; 1986 Jun; 46(6):2751-5. PubMed ID: 3009000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of prochlorperazine on experimental nephrotoxicity.
    Harrison SD; Cox JL; Giles RC
    Cancer Chemother Pharmacol; 1982 Dec; 10(1):62-7. PubMed ID: 6218930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron- and ascorbic acid-induced lipid peroxidation in renal microsomes isolated from rats treated with platinum compounds.
    Hannemann J; Duwe J; Baumann K
    Cancer Chemother Pharmacol; 1991; 28(6):427-33. PubMed ID: 1934247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal circadian clock regulates the dosing-time dependency of cisplatin-induced nephrotoxicity in mice.
    Oda M; Koyanagi S; Tsurudome Y; Kanemitsu T; Matsunaga N; Ohdo S
    Mol Pharmacol; 2014 May; 85(5):715-22. PubMed ID: 24567546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.